文献速递慢性肾脏病肾血管病与高血压

APOL1基因型与HIV感染:20年CKD、心血管疾病及高血压结局

APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension.
PubMed 文献 · Kidney Int Rep · 2024-12-21

在1194例接受治疗的HIV感染黑人中,APOL1风险等位基因与CKD发生及eGFR下降相关,包括1个风险等位基因的效应在随访第二十年才显现;未发现与高血压或心血管疾病的相关性。持续病毒抑制未改变CKD关联,但与更慢的eGFR下降和更少蛋白尿相关。

要点

  • APOL1风险等位基因与CKD风险增加相关,1个等位基因的效应需长期随访才显现。
  • APOL1风险等位基因与高血压或心血管疾病发生无显著关联。
  • 持续HIV病毒抑制可减缓eGFR下降和减少蛋白尿,但不改变CKD关联。

核心结论

  • 在接受治疗的HIV感染黑人中,APOL1风险等位基因与CKD和eGFR下降相关,1个风险等位基因的效应较晚显现且在不持续病毒抑制者中更明显。
  • 未检测到APOL1风险等位基因与高血压或心血管疾病发生的关联。

研究设计与样本

  • 基于ACTG观察性研究A5001和A5322,纳入1194例HIV感染黑人进行APOL1风险等位基因分型。
  • 使用Cox比例风险模型评估APOL1基因型与CKD、CVD和高血压发生的关联,线性混合效应模型分析纵向eGFR和蛋白尿。
  • 评估血浆HIV-1病毒抑制作为效应修饰因子。

主要发现

  • APOL1基因型与CKD发生相关,但与高血压或CVD无关,尽管该相对年轻队列中CVD事件不频繁。
  • 携带APOL1风险等位基因者eGFR年下降率和蛋白尿更高,包括1个风险等位基因的有害效应在随访第二十年才显现。
  • 持续HIV-1病毒抑制未改变APOL1基因型与新发CKD的关联。
  • 在至少携带1个APOL1风险等位基因的参与者中,持续病毒抑制与更慢的eGFR下降和更少蛋白尿相关,包括随访期间eGFR始终高于CKD阈值的个体。

临床怎么用

  • 对HIV感染黑人进行APOL1基因分型可能有助于识别CKD高风险个体,尤其是携带1个风险等位基因者需长期监测。
  • 维持持续HIV病毒抑制可能减缓APOL1相关eGFR下降和蛋白尿,即使eGFR尚在正常范围。

局限性

  • CVD事件在该相对年轻队列中不频繁,可能限制检测关联的统计效能。
  • 研究人群为HIV感染黑人,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: APOL1 variant alleles substantially increase the risk for chronic kidney disease (CKD) in Black individuals, especially in the setting of HIV infection; however, their impact on hypertension and cardiovascular disease (CVD) is unclear. METHODS: Black persons with HIV (n = 1194) followed in the AIDS Clinical Trials Group (ACTG) observational studies A5001 and A5322 were genotyped for APOL1 risk alleles. Cox proportional hazard models were used to assess associations between APOL1 genotype and incident CKD, CVD, and hypertension, and linear mixed effects models were used to examine associations with longitudinal estimated glomerular filtration rate (eGFR) and proteinuria. Plasma HIV-1 viral suppression was evaluated as an effect modifier. RESULTS: APOL1 genotype was associated with CKD, but not with hypertension or CVD, although CVD events were infrequent in this relatively young cohort. Annual rates of eGFR decline and proteinuria were greater among persons with APOL1 risk alleles, including a detrimental effect of 1 APOL1 risk allele, which only became evident in the second decade of follow-up. Sustained HIV-1 viral suppression did not alter the association between incident CKD and APOL1 genotype; however, it was associated with a slower rate of eGFR decline and less proteinuria in participants with at least 1 APOL1 risk allele, including individuals with eGFRs above the CKD threshold throughout follow-up. CONCLUSION: Among treated persons with HIV, APOL1 risk alleles were associated with CKD and eGFR decline, including an effect of 1 APOL1 risk allele which took longer to manifest and was greater in individuals who did not achieve sustained viral suppression. Conversely, no association between APOL1 risk alleles and incident hypertension or CVD was detected.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tassiopoulos KK, Wu K, Wu Z, et al. APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension. Kidney Int Rep. 2024. PMID: 40225368. doi:10.1016/j.ekir.2024.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。